Clinical Trial

CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis

Name: CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis — clinical trial record (NCT06785519)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Early Phase 1

View on ClinicalTrials.gov →

Summary

A Clinical Study of the Safety and Efficacy of CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis.

Trial Details

NCT Number	NCT06785519
Lead Sponsor	He Huang Collaborators: Yake Biotechnology Ltd.
Conditions	Lupus Nephritis
Enrollment	9 participants
Start Date	2025-01-31
Primary Completion	2027-10-31 (estimated)
Study Completion	2027-10-31 (estimated)
Updated on ClinicalTrials.gov	2025-01-21